

PTO/SB/08A (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE sons are required to respond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction

Substitute for form 1449A/PTO				Complete if Known		
				Application Number	09/246,129	
INFORMATION DISCLOSURE				Filing Date	February 8, 1999	
l s	TATEMENT I	3Y A	APPLICANT	First Named Inventor	Guo-Liang Yu	
				Art Unit	1647	
	(use as many she	ets as	necessary)	Examiner Name	D. Romeo	
Sheet	1	of	1	Attorney Docket Number	PF141P4	

			U.S. PATE	NT DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
					Figures Appear

	FOREIGN PATENT DOCUMENTS						
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant		
Initials*	No.1	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	T ⁶	
#R	СС	PCT-WO 99/23105-B2		Human Genome Sciences, Inc.			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹Applicant's unique citation designation number (optional). ²See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

		OTHER – NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
AR	CD	ZHAI et al. "VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo" FASEB Journal 13(1):181-189, JANUARY 1999.	
	CE	Datábase EMBL 'Online!, Database Accession No. AF039390 (December 21, 1998)	
4R	CF	Supplementary Partial European Search Report, Application No. EP 99 90 5874	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature	7	James Romes	Date Considered	7/21/3	

¹Applicant's unique citation designation number (optional). 2Applicant is to place a check mark here if English language Translation is attached.